Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation
Recruiting · NCT06894628 · Observational (researchers observe without assigning treatment) · Lead sponsor: Regina Elena Cancer Institute
View the official record on ClinicalTrials.gov →What this trial is about
The study aims to validate the Decipher® genomic test, in which patients with biochemical recurrence after radical prostatectomy are treated with salvage radiotherapy with extreme hypofractionation (5+ Gy/fraction). Validating the Decipher® genomic classifier based on the expression of 22 RNA genes in the prospective study "esSBRT"
Who can take part
Age range
No age limits stated
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- patients enrolled at IRE under the "esSBRT" protocol (meeting the criteria of the same);
- patients who express written informed consent personally or through their legal representative/witness/curator/guardian/support administrator (participation in the ancillary study and data processing)
Exclusion criteria
- all exclusion criteria adopted for the "esSBRT" study.
Where it is running
1 location listed.
- IRCSS Regina Elena - Roma, Italy